



connections newsletter



**JULY 2019
UPDATE**

**Serving the NC Life
Sciences Industry**

<http://ncbioscience.net>
919-281-8960

[home](#) | [about](#) | [calendar](#) | [news](#) | [member benefits](#) | [forums](#) | [advocacy](#) | [contact](#)

NCBIO This Month

- Lawmakers Hear about North Carolina’s Role in Genomic Medicine
- Plant and Animal Production Topics for Caucus Meetings
- State Budget Negotiations Under Way at General Assembly
- Workplace Safety and Human Performance Focus of Safety Summit
- Sergi Roura Receives NCBIO Award
- Luncheon and Forum: Lab Space in NC, July 16
- NCBIO Annual Meeting, October 3
- NCSU to Lead \$30M Crop Resilience Research Program
- BRITE Offers Summer Workshops
- Triad BioNight
- BIO 2019 Convention Review



- **At the National Level**
- Member News
- Member Benefits
- Calendar

NCBIO - Media

Find the latest news from NCBIO on the website ncbioscience.net, on [LinkedIn](#) and on Twitter at [@ncbio](#).

NCBIO Links

[CED](#)

[NCBIO](#)

[NC Biotech Center](#)

[BRITE](#)

[BTEC](#)

[BioNetwork](#)

[NCBioImpact](#)

[North Carolina
Pharmaceutical Services
Network](#)

[NCABR](#)

[National Center for
Biotechnology Workforce](#)

Lawmakers Hear about North Carolina’s Role in Genomic Medicine



Sara Imhof, Jude Samulski, Rep. David Lewis, Jay Griffin, Sam Taylor

NCBIO Sustaining Members

Biogen



NCBIO and BIO hosted a one-hour session at the General Assembly this month to brief lawmakers on Genomic Medicine, including North Carolina’s leadership position in

bringing new genomic medicines to market. The program included information regarding:

- Health conditions that can be addressed through genomic medicine
- Why North Carolina is a leader in genomic medicine research and manufacturing
- The economic impact and opportunities that genomic medicine companies bring to North Carolina
- The value that genomic medicine brings to a patient and their family
- Access and affordability

Dr. Samulski, Ph.D., Founder of Bamboo Therapeutics and AskBio and Director of the Gene Therapy Center, UNC-Chapel Hill, told lawmakers about the impact gene therapy can have on rare diseases, explaining that “approximately 7,000 rare diseases have been identified and more are being discovered each day.” In the United States, any disease affecting fewer than 200,000 people is considered rare.

Samulski also noted that rare diseases affect 30 million Americans, or 1/10 of our population, and 350 million worldwide. “Approximately 50% of those affected are children, Samulski said, noting that “many of these children will not live to see their fifth birthday.” “Furthermore,” said Samulski, “ninety-five percent of rare diseases do not have a single treatment or cure. Providing better treatments can improve quality of life, prolong life for rare disease patients, and reduce the cost of health care.”

Sara Imhof, Ph.D., Senior Director, Precision Health, North Carolina Biotechnology Center, reviewed the economic impact of gene and related therapies in North Carolina. She outlined healthcare, academic and industry collaborations. She noted that announced industry investments in gene therapy research and manufacturing in North Carolina has now reached nearly \$300M. Imhof also discussed the work of the Biotechnology Center’s Precision Health Collaborative, which is bringing together health policy thought leaders to discuss the impacts of precision medicine.

Jay Griffin, parent and Duchene Muscular Dystrophy patient advocate, talked about the impact the disease has had on his son and the impact gene therapy could have on patients and their families.

NCBIO President Sam Taylor outlined for lawmakers how North Carolina has become one of the nation’s leading hubs for gene therapy research, commercialization and manufacturing. Taylor said, “Our goal for the session was to provide legislators a clear picture of the technologies, companies and positive health care outcomes that have resulted in the Assembly’s funding for the life sciences.”

[Back to top.](#)

Plant and Animal Production Topics for Caucus Meetings



Dan Jenkins (Pairwise), Rep. Robert Rieves, Tom Adams (Pairwise) and Sen. Mike Woodard

The General Assembly’s Life Science Caucus met jointly in June with the Assembly’s Agriculture and Rural Caucus. The two groups used the opportunity to learn of new life science technologies promising to bring better crops and improved livestock management to farmers. Guest presenters included representatives of NCBIO members Pairwise and Premex.

Tom Adams, CEO of Pairwise, told lawmakers his company decided to locate in North Carolina because of the diversity of agriculture in the State and the researchers at the universities. He discussed the company’s efforts to change where berries and fruits can be grown and research on how to extend shelf life and create other improvements in fruits and vegetables.

Lilly



Novartis



Pfizer



We Work For Health



NCBIO Supporting Members

Cook Medical



Merck



VWR





Anne Ballou (Premex)

Anne Ballou, Lead Scientist at Premex's North Carolina research center, reviewed the company's research on animal health, especially the need to understand the microbiomes of livestock digestive tracts. Among other things, Premex hopes to exploit microbiomes' capacity to stimulate the immune system and improve animal health.

Life Science Committee Co-Chair Senator Mike Woodward (D-Durham), who presided at the meeting, said there would be more joint caucus meetings in the future along with joint trips to facilities in other parts of the State following the General Assembly's session.

NCBIO President Sam Taylor said, "This was a very successful meeting with a lot of good questions about plant and animal research and product development. We look forward to coordinating more joint meetings in the future."

[Back to top.](#)

State Budget Negotiations Under Way at General Assembly



House and Senate budget leaders are working their way through differences in respective versions of their 2019-21 appropriations legislation. Appropriations leaders must agree on compromise legislation and bring a final bill to the floor for votes in each chamber. The appropriations legislation must then be signed by Governor Roy Cooper, who has expressed concerns about both the House and Senate spending plans.

There are major differences between the House and Senate proposed appropriations for programs affecting the life science industry. The House Budget includes \$500,000 in additional recurring funding for the North Carolina Biotechnology Center, and \$400,000 in non-recurring funding for the 2019-20 fiscal year. The Senate budget does not include additional funding for the Center. The House appropriation would be used to expand the Center's business recruitment and start-up loan programs.

The House budget also includes \$1M in non-recurring funding in both years of the 2019-21 biennium for the State's SBIR/STTR matching grant program, commonly known as the One North Carolina Small Business Program. The Senate budget does not have funding for the matching program.

Both House and Senate proposals provide \$2M for each year of the biennium for North Carolina's participation in the National Institute for Innovation in the Manufacturing of Biopharmaceuticals (NIIMBL). These funds will be managed by North Carolina State University and distributed to support workforce development or biomanufacturing process innovation projects at participating institutions across the State.

Both proposals also include major reductions to the State's franchise tax and implementation of market-based sourcing for North Carolina businesses. The franchise tax reductions include a \$150,000 cap on any company's total franchise tax liability. In addition, the tax would see a phased reduction from the current \$1.50 per \$1000 in tax base to \$1.00 per \$1000 beginning in 2021.

Market-based sourcing would change rules governing the State to which companies' sales are attributed for sales and income tax purposes. The biggest change would shift the attribution of income from services from the State in which the service is performed to the State in which the customer is located. Contract research organizations in North Carolina could benefit significantly from the change.

NCBIO is monitoring the budget negotiations and working to support State House's appropriations to the North Carolina Biotechnology Center and the One North Carolina Small Business Program.

[Back to top.](#)

Workplace Safety and Human Performance Focus of Safety Summit



Jennifer Bailey, Steve Quesnelle, Peter Self, Tom Wilson and Todd Conklin

Todd Conklin challenged participants at the NCBIO Biotech Manufacturers Safety Summit to change some of their traditional views about safety in the workplace. Conklin, author of *Simple Revolutionary Acts: Ideas to Revitalize Yourself and Your Workplace*, said that the traditional viewpoint is that "Workers are the problem to be fixed." He countered that "Workers are not the problem. They are the problem solvers." He talked about the importance of encouraging workers to understand their environments noting that "Safety is not the absence of accidents rather safety is the presence of defenses." Conklin reinforced the importance of "shifting thinking from who failed to what failed."

Peter Self, Associate Director, Environmental, Health, Safety and Sustainability, at Biogen opened the day's activities noting the importance of integrating human performance principles into Biogen's operations, which helps drive continuous improvement. Biogen was a sponsor of the event and also served as the host site for the Summit.

Tom Wilson, the sole survivor of a plane crash in Canada that killed seven other people, talked about the importance of courage. Wilson is author of a book about his experience, *Moments of Impact*. He talked about the importance of individuals taking a risk and having the courage to speak up when they recognize a safety issue. He noted that if he or others had spoken up about the weather problems the day of the plane flight, the crash could have been avoided. He outlined 10 areas for hazard and safety identification.

Jennifer Bailey with Alabama Power Company & Southern Company outlined steps her organization has taken to help change behavior, encouraging reporting of incidents and using positive reinforcement to break down barriers to safety, which in-turn have significantly reduced significant injury and fatality rates.

Roger Paules and Ray Best of Duke Energy discussed steps the organization takes to help companies with emergency and disaster situations.

Thanks to [Biogen](#), [Duke Energy](#) and the NCBIO Biotech Manufacturers Forum (BMF) members for sponsoring this event. For more information about the Summit or BMF, contact [John Wagner](#) or [Brenda Summers](#).

[Back to top.](#)

Sergi Roura Receives NCBIO Award

The NCBIO Biotech Manufacturers Forum (BMF) presented Sergi Roura of Grifols with the NCBIO Life Science Service Award. The award recognizes outstanding contributions to industry and community. BMF Program Manager John Wagner presented the award at BMF Site Leaders workforce meeting in June.



[Sergi Roura and John Wagner](#)

Roura is currently transitioning to a new global responsibility as Grifols' President of Commercial Technical Support and returning to Spain. For the last two years he has served as North America Facilities President. He served as site head of Grifols Clayton beginning with Grifols' acquisition of the site from Talecris in 2011.

"Sergi has been an advocate of our efforts to improve workforce recruitment and training. He has supported the growth of the industry in North Carolina and the expansion of the Clayton facility. This award is a recognition of his many contributions to the life science industry in the State," stated John Wagner, NCBIO BMF Program Manager in presenting the award.

Roura said, "I have enjoyed serving in many capacities at Grifols and with the North Carolina Workforce Commission, the North Carolina Biotechnology Center Board of Directors, and working with NCBIO on workforce and waste water issues. This is an honor for Grifols to receive this recognition."

NCBIO President Sam Taylor said, "Sergi has been an advisor on issues affecting the industry and has brought a long-term view to ensuring a strong talent and infrastructure base for the industry. We are pleased that in his new global role he will still return to North Carolina periodically. We wish him the best with his new opportunities."

[Back to top.](#)

Luncheon and Forum: Lab Space in NC, July 16

Join life science representatives on July 16 from 11:30 a.m. to 1:30 p.m. at the NC Biotech Center (RTP) to learn about available [lab spaces in the state](#). Attendees will also hear about strategies for finding, leasing and/or procuring space depending on business and scientific objectives, and age and stage of company. The program will be moderated by **Bill Bullock**, Senior Vice President, Economic Development and

Statewide Operations, [NC Biotechnology Center](#). Panelists joining the conversation include:

- **Matthew Cooke**, Principal, Corporate Advisory Services Division, [Davis Moore](#)
- **Ed Field**, President, [BioLabs North Carolina](#)
- **Andy Schwab, Ph.D.**, President, [First Flight Venture Center](#)
- **Neill Sherron**, Director of Leasing, [Longfellow Real Estate Partners](#)

Thank you to our sponsors: [Davis Moore](#), [Longfellow Real Estate Partners](#), and [VWR](#).

NCBIO members can register [online](#) or contact [Amber Niebauer](#) for assistance.

[Back to top.](#)

NCBIO Annual Meeting, October 3



On October 3 from 8:00 a.m. to 3:00 p.m., more than 200 NCBIO members will come together for NCBIO's 25th [Annual Meeting](#) at the NC Biotech Center. Members and their guests will have the opportunity to hear from life science leaders and network with one another. Attendees will hear from two keynote speakers:

- **Marty Murphy**, Former Chief Executive Officer and Founder, Hipple Cancer Research Center; Co-founder, Society for Translational Oncology, talks about new innovations around personalized health and cancer treatment.
- **Peter Meath**, Managing Director, Industry Head – Life Sciences, Commercial Banking, J.P. Morgan, and **Lauren Ruane**, Managing Director, Equity Capital Markets, J.P. Morgan, take a deep dive into the economics of the life science space and the economic cross currents that industry is navigating.

Additionally, there will be two panel sessions focused on the ag and human microbiome, and access and availability. Networking opportunities include break, lunch, and a dessert reception to celebrate NCBIO's 25th Anniversary. To learn more about sessions and speakers or to register, [click here](#) or contact [Amber Niebauer](#) for assistance.

Thank you to our current sponsors:

Platinum: [BIO](#), [Bioventus](#), [Cook Medical](#), and [VWR](#)

Gold: [FUJIFILM Diosynth Biotechnologies](#)

Silver: [Charter Medical](#), [Office Depot](#), [The Conafay Group](#), [UCB](#)

Bronze: [Business Wire](#), [G1 Therapeutics](#), [Novozymes](#)

[Back to top.](#)

NCSU to Lead \$30M Crop Resilience Research Program

From NCBiotech

North Carolina State University (NCSU) will lead a new \$30 million research program intended to make crops more resilient against environmental stresses while reducing the need for chemical treatments and irrigation. NCSU will receive about \$8 million of the program's funding over six years to study how microbes in soil, roots and leaves interact with plants and affect plant health and productivity.

The research will be carried out by the Collaborative Crop Resilience Program (CCRP) with funding from the [Novo Nordisk Foundation](#), the parent organization of [Novozymes](#), a Danish life sciences company and research partner of NCSU. [More](#)

[Back to top.](#)

BRITE Offers Summer Workshop

Come hear from industry professionals about career paths and current trends in clinical research, July 16, 1-4 PM at BRITE at NCCU. Participants will learn and discuss:

- The new Clinical Research Science Program and NCCU
- Current issues in clinical research
- Career advice and career path information
- Networking opportunities with industry partners

For more information, contact [Roslyn Lewis](#).

BRITE is also offering a Professional Development Communications Workshop Tuesday, July 23rd, 8:30am-4:30pm (*Breakfast begins at 7:30am*), BRITE Bldg., Room 1050.

This interactive all day Workshop, led by 3rd Degree Solutions CEO, Me'chelle McKenney, will cover such topics as: Giving and Receiving Feedback, Communication Skills for Professionals, Coping with Difficult Co-workers and Multiple Generations in the Work Place. The cost is \$100 for attendees, which includes both breakfast and lunch for the day. For additional information contact, Academic Advisor/Recruiter-BRITE, [Natacha Janvier-Derilus](#) or call 919-530-7717.

[Back to top.](#)

Triad BioNight



David Hollinrake (Syngenta) and Nancy Johnston (NCBiotech)

More than 300 people turned out for Triad BioNight at the Grandover Hotel in Greensboro. David Hollinrake, Region Director and North America President of Syngenta Seeds, was the keynote speaker. He discussed the "Five Megatrends in Agriculture."

NCBIO Board Member Russ Read, Executive Director of the Winston-Salem-based [National Center for the Biotechnology Workforce](#), received the Academic Development Excellence award. Kenneth Russell, Director of Medical Device Development, at [Wake Forest Innovations](#) in the Wake Forest School of Medicine, received the Biotechnology Service/Support Excellence award.

The "Body-on-a-Chip" team at the [Wake Forest Institute for Regenerative Medicine](#), including Anthony Atala, M.D., Colin Bishop, Ph.D., Adam Hall, Ph.D., John Jackson, Ph.D., Sang Jin Lee, Ph.D., Sean Murphy, Ph.D., Tom Shupe, Ph.D., Aleks Skardal, Ph.D., Shay Soker, Ph.D., and James Yoo, M.D., Ph.D. received the Research and Development Excellence award. Yonnie Butler, Executive Director of the [Biotechnology Center of Excellence](#), at Alamance Community College (ACC), received the

Biotechnology Community Leadership Excellence award. Jennifer Byrne, Chief Executive Officer and Board Chair of [Javara](#), an Integrated Research Organization (IRO) in Winston-Salem received the Entrepreneurial Excellence award. [More](#)

[Back to top.](#)

BIO 2019 Convention Review

In a keynote address at the BIO 2019 International Convention, CEO Jim Greenwood noted how politicians and patients are talking about different things when discussing drug costs in the United States and why those differences represent a threat to transformative breakthroughs currently in the development pipeline.

Greenwood said, "The world is beginning to grasp that we've entered the dawn of a golden age of medicine. It's an age of hope. It's an age of possibility. And it's an age of healing. No disease will escape our scientists anymore. None. It's not just big pharma companies filling the FDA pipeline. It's actually small and emerging biotech companies driving nearly four in five drug programs through the clinic today. And what's coming out of their labs in terms of genomic breakthroughs is like nothing we've ever seen before." [More](#)

[The BIO International Convention](#) was held in Philadelphia, June 3-6. One Convention session focused on "Gene Therapy 2.0: No Longer Science Fiction." [More](#).

A [distinguished panel](#) of deal-makers gathered on the third day of the 2019 BIO International Convention to discuss how these market forces will likely affect biotech and pharmaceutical deals in the future, drawing upon the [Syneos Health Dealmakers' Intentions Study](#) and the BIO One-on-One Partnering Forecast. [More](#).



[Commerce Secretary Tony Copeland speaks at NC Reception](#)


On Tuesday evening, June 4, N.C. Department of Commerce Secretary Tony Copeland welcomed more than 200 attendees to the Barnes Foundation for the North Carolina Reception. Secretary Copeland shared details about North Carolina's thriving life science cluster, more than 700 companies and 64,500 employees strong. The crowd celebrated the state's recent wins – from gene and cell therapy companies AveXis and Collectis to recent announcements by KriGen, Parexel and Tergus.

The North Carolina Reception will return for next year's BIO in San Diego, June 8-11, 2020. For more 2019 highlights of the BIO Convention, [click here](#).

[Back to top.](#)

At the National Level

Senator Tillis Defends Patent Law Protections



NCBIO President Sam Taylor issued the following statement regarding Senator Thom Tillis' defense of the fundamental tenants of patent law at recent U.S. Senate Judiciary Committee hearings concerning proposals that would undermine or eliminate patent protections for pharmaceutical products.

"NCBIO and its member pharmaceutical companies thank Senator Thom Tillis for his cogent explanation of the adverse impacts of proposals to deprive American pharmaceutical innovators of certain patent protections. It is uncontroverted that the current patent system enables and incentivizes the continuous development and advancement of new treatments – and even cures – for human health conditions. Senator Tillis is indeed correct, that erosion of patent protections can do more harm than good to American patients."

"America's pharmaceutical industry leads the world in the development of new drugs. And North Carolina is a national leader in the manufacturing of innovative, safe and effective drug products. These products are not immediately conceived in their most optimal form by any inventor or company. They are the product of an innovation process that should be honored and preserved. NCBIO urges the Senate Judiciary Committee to avoid precipitous action, and to give full and careful consideration to any changes to existing patent law. Above all, we ask that the Committee take no action that will reduce the protections afforded American patent holders and their licensees."

Medical Device Tax Repeal

The US House Ways & Means Committee held a hearing during which members of Congress called attention to a number of crucial policy issues, including repeal of the medical device excise tax.

"We want to thank Committee members Jackie Walorski (R-Ind.) and Devin Nunes (R-Calif.) and Rep. Dean Phillips (D-Minn.) for their commitment to repeal this burdensome tax," said Scott Whitaker, President and CEO of the Advanced Medical Technology Association (AdvaMed). "Without action, by the end of the year the industry will face a massive tax increase which will throw an anchor around the neck of an industry that is doing so much to improve patient care and grow the U.S. economy."

"Legislation to repeal this onerous tax has strong bipartisan support in both the House and Senate as well as with the Administration. There is no reason for Congress to delay further action to get rid of this anti-patient, anti-innovation tax once and for all," continued Whitaker. [More](#)

NCBIO Members get Discount for The MedTech Conference

Join AdvaMed on September 23-25 as 3,000+ of the world's top medtech executives gather in Boston for [The MedTech Conference](#). The event features world-class plenary speakers, cross-cutting programming, valuable networking and business development opportunities. NCBIO members can save 10% on [registration](#). Contact [Amber Niebauer](#), NCBIO Events Director, for the discount code. Early bird registration ends July 26.

[Back to top.](#)

Member News

To be included in Member News, send information about your organization to [Brenda Summers](#)

[AveXis](#), a [Novartis](#) company, announced innovative access programs for Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (*SMN1*) gene. AveXis is working closely with payers to offer pay-over-time options up to 5 years and outcomes-based agreements up to 5 years, as well as providing a patient program to support affordability and access. [More](#)

[BASF](#) opened its new global Agrochemical Application Research Center (AARC) in Research Triangle Park. The facility will help to further optimize stewardship guidelines regarding on-target application of BASF crop protection products used worldwide. Research conducted at the facility will also address application buffer zones for the company's products as well as specific tank mix combinations. [More](#)

[Biogen](#) announced that it has completed its acquisition of Nightstar Therapeutic, a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of the acquisition, Biogen now has added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. [More](#)

[Bioventus](#) has entered into a development collaboration agreement with MTF Biologics, the world's largest tissue bank, to co-develop a next generation placental tissue product for the treatment of painful musculoskeletal conditions, with an initial focus on knee osteoarthritis (OA). [More](#)

[Chiesi](#) announced it has received a B Corporation Certification. The announcement comes from B Lab, a non-profit body that serves a global movement of people using business as a force for good. B Lab assessed the social and environmental performance of all 28 Chiesi affiliates, on the basis of the B Impact Assessment (BIA), the most widely-used assessment for measuring the impact of a company on its workers, community, environment and customers: a global standard, as well as a benchmark tool with over 70,000 companies in the world. [More](#)

[G1 Therapeutics, Inc.](#) announced preliminary overall survival (OS) results from a randomized Phase 2 trial which demonstrated that women with metastatic triple-negative breast cancer (mTNBC) lived significantly longer when receiving trilaciclib and chemotherapy compared with women receiving chemotherapy alone. [More](#) G1 Therapeutics, Inc. announced that current board member Garry Nicholson has been named as board chair, succeeding former chair Seth Rudnick, M.D. Dr. Rudnick, Sir Andrew Witty and Fredric Eshelman, Pharm.D. have been re-elected to the Company's Board of Directors. [More](#)

[Novozymes](#) announced two major launches during the [Fuel Ethanol Workshop & Expo](#) (FEW) to continue supporting the growth of the renewable fuel industry. *Fortiva* is a new alpha-amylase technology that helps customers avoid having to choose between maximizing enzyme performance and operational efficiency. In yeast, *Force* continues to deliver on the promise to quickly bring innovative, robust, and reliable biological solutions to the market from the Innova yeast platform established last year. [More](#)

[Pfizer Inc.](#) and Array BioPharma Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. [More](#)



[Sage Therapeutics](#) cut the ribbon for Sage Central – a full service, end-to-end patient support center in the Triangle. The company also announced that the U.S. Drug Enforcement Administration (DEA) has placed ZULRESSO™ (brexanolone) injection into Schedule IV of the Controlled Substances Act. ZULRESSO, which was approved by the

U.S. Food and Drug Administration (FDA) on March 19, 2019, This is the first and only treatment specifically approved for postpartum depression (PPD), the most common medical complication of childbirth. [More](#)

[Seqirus](#) in Holly Springs was featured in a three-part series on influenza pandemics on the PBS NewsHour. The series focuses on preparations for a pandemic and development of flu vaccines. [More](#)

[Back to top.](#)

NCBIO Member Benefits – New Discounts from NCBIO Member Companies



NCBIO Member Benefits

Last year BIO saved 4,200 companies nearly \$460 million through BIO Business Solutions® with volume-based discounts and favorable contract terms on lab supplies, waste removal, microscopes, shipping, gases, and more.

Last year BIO saved 4,200 companies nearly \$460 million through BIO Business Solutions with volume-based discounts and favorable contract terms on lab supplies, waste removal, microscopes, shipping, gases, and more.

As an NCBIO member, you are eligible! This is a benefit of your NCBIO membership. Review the cost-savings offered by clicking [here](#) and choose the programs you're interested in. Email biobusinesssolutions@bio.org with your choices and they will get you started. For all the latest news, promos, and event information, follow [BIO Business Solutions on LinkedIn!](#)

BIO-Airgas Cost-Savings Program

Airgas Healthcare
an Air Liquide company

BIO's preferred partner for packaged and bulk gases, Airgas, offers BIO members up to 25% off select cryogenic equipment, gas distribution equipment, safety products, and much more.

- Hotlist of medical-grade nitrogen, helium, argon & carbon dioxide, plus custom offerings tailored to specific member needs
- Customized product service agreement for renewal, removal, and remedy terms and guaranteed price savings option
- National sales and support combined with local industry specialists to assist your business
- Full supply mode services: Cylinders, Dewars, Microbulk, Bulk and Pipeline, and Dry Ice services

[LEARN MORE](#)

Who would you trust with your research?



Looking to make a move? BIO's preferred partner for moving and storage services, Humboldt, has been in the business of moving everything from home furnishings to specialized equipment for over a century. Humboldt offers BIO members deep discounts on:

- Lab Moves
- Office Moves
- Employee Relocation
- Even Personal Moves!

Read Humboldt's latest [case study](#) on a recent lab move for a therapeutics company in the Boston area.

[LEARN MORE](#)

About Bio Business Solutions

BIO Business Solutions is the largest cost savings purchasing program for the biotech industry, operated by the Biotechnology Innovation Organization (BIO). BIO leverages the purchasing power of the industry to negotiate with top suppliers to secure exceptional savings, favorable terms, and superior service for members. BIO members can participate for no charge as a benefit of their membership and to save on items they need to run a successful biotechnology enterprise.

[Back to top.](#)

Calendar

To view full calendar, [click](#).

[Durham Tech Molecular Biology Techniques](#)

Tuesday Jul 2, 2019

... [read more](#)

[BTEC Hands-On cGMP Biomanufacturing Operations](#)

Tuesday Jul 9, 2019 - Friday Jul 12, 2019

... [read more](#)

[Becoming an Investor-Ready Entrepreneur](#)

Thursday Jul 11, 2019

... [read more](#)

[STOPfakes.gov Roadshow Raleigh](#)

Thursday Jul 11, 2019

... [read more](#)

[LaunchBio: Larger than Life Science](#)

Thursday Jul 11, 2019

... [read more](#)

[NCBIO Life Sciences Luncheon and Forum: Lab Space in North Carolina - July 2019](#)

Tuesday Jul 16, 2019

... [read more](#)

[Global Health Leadership Forum: North Carolina's Global Public Health Connections](#)

Tuesday Jul 16, 2019

... [read more](#)

[Digital Health Happy Hour](#)

Wednesday Jul 17, 2019

... [read more](#)

[BTEC Cell Culture Engineering: A Single-Use Perspective](#)

Tuesday Jul 23, 2019 - Thursday Jul 25, 2019

... [read more](#)

[BTEC Biopharmaceutical Assay Essentials](#)

Tuesday Jul 23, 2019 - Friday Jul 26, 2019

... [read more](#)

[BTEC Applied Cleaning Validation Practices: A STERIS Master Class](#)

Tuesday Jul 30, 2019 - Wednesday Jul 31, 2019

... [read more](#)

[BTEC Fermentation Engineering](#)

Tuesday Jul 30, 2019 - Thursday Aug 1, 2019

... [read more](#)

[Back to top.](#)

North Carolina Biosciences Organization © copyright 2019

email: bsummers@ncbioscience.net phone: 919-281-8960 web: <http://ncbioscience.net>



NCBIO
P.O. Box 14354
Research Triangle Park
North Carolina 27709

